TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03845088

Intervention type: PROCEDURE
Intervention: temporomandibular jont reconstruction with costochondral transplantation
Description: temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
Study: NCT05128799

Intervention type: OTHER
Intervention: 3 Wishes Program (3WP)
Description: The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds.
Study: NCT01708369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 150 mg orally
Study: NCT00442559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
Study: NCT01708369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 650 mg orally will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 650 mg orally will be given
Study: NCT00700466

Intervention type: DRUG
Intervention: i.v. beta-blocker infusion (metoprolol)
Description: A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
Study: NCT01751490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder stabilisation surgery
Description: arthroscopic stabilisation surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder stabilisation surgery
Description: arthroscopic stabilisation surgery
Study: NCT03085940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg once daily initially
Study: NCT02378545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask.
Study: NCT03143270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
Study: NCT05209685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise on the lower extremities
Description: Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise on the lower extremities with blood flow restriction
Description: Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
Study: NCT04366440

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Order set review and modification with facilitation
Description: The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.

Intervention type: OTHER
Group type: OTHER
Intervention: Order set review and modification
Description: The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
Study: NCT00806546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101
Description: NP101 study patch four hour application
Study: NCT02825303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace consisting of two height-adjustable desks
Description: Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace consisting of two height-adjustable desks
Description: Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
Study: NCT02751177

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
Description: Mutation in plasma DNA vs tumor tissue
Study: NCT01071512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tysabri
Description: Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
Study: NCT04275596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2QR complex
Description: Application of topical gel containing 2QR complex on the anal wound until complete wound healing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Application of topical placebo on the anal wound until complete wound healing
Study: NCT01664013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuronox
Description: Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
Study: NCT02102633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 150 mg orally
Study: NCT03085940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02751658

Intervention type: OTHER
Group type: OTHER
Intervention: mouth swab
Description: Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
Study: NCT00442559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled corticosteroid
Description: Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
Study: NCT04009109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction and Maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction and Maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Induction and Only Maintenance Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Induction and Only Maintenance Arm B
Study: NCT01333501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg in capsules for oral administration once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1b
Description: 250 μg injected s.c. every other day
Study: NCT02405624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: CPAP training for muscle strength
Study: NCT04276532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node sampling (SLN)
Description: Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic lymphonodectomy (PLN)
Description: Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
Study: NCT01574924

Intervention type: OTHER
Intervention: No intervention.
Description: There are no interventions in this observational study.
Study: NCT00852657

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tendon repair with acromioplasty
Description: Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: According to a rehabilitation program which was established prior to study start.
Study: NCT04098991

Intervention type: DRUG
Intervention: Levothyroxine
Description: All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
Study: NCT03935282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AH-HA Tool in the EPIC EHR
Description: The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
Study: NCT02426359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q301 Cream
Study: NCT04009109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Induction and Only Maintenance Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Induction and Only Maintenance Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction and Only Maintenance Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction and Only Maintenance Arm B
Study: NCT01916525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise based cardiac rehabilitation
Description: The cost-effectiveness between the exercise training vs. control groups
Study: NCT00531167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of lamivudine+adefovir vs entecavir
Description: Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination of lamivudine+adefovir vs entecavir
Description: Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
Study: NCT05224388

Intervention type: DRUG
Intervention: Enoxaparin
Description: Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen

Intervention type: DRUG
Intervention: Enoxaparin
Description: Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen

Intervention type: DRUG
Intervention: Enoxaparin
Description: Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen

Intervention type: DRUG
Intervention: Enoxaparin
Description: Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen

Intervention type: DRUG
Intervention: Heparin
Description: Use of heparin in either prophylactic dose regimen or therapeutic dose regimen

Intervention type: DRUG
Intervention: Heparin
Description: Use of heparin in either prophylactic dose regimen or therapeutic dose regimen

Intervention type: DRUG
Intervention: Heparin
Description: Use of heparin in either prophylactic dose regimen or therapeutic dose regimen

Intervention type: DRUG
Intervention: Heparin
Description: Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
Study: NCT01508117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
Study: NCT02426359

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03175068

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
Study: NCT01979211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
Study: NCT03277391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled analgesia
Description: Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled analgesia
Description: Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
Study: NCT03175068

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ST
Description: Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
Study: NCT00981331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtalar joint manipulation
Description: The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham subtalar joint manipulation
Description: The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
Study: NCT04943601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: action observation therapy
Description: The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
Study: NCT04395625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct bonding of Orthodontic brackets
Description: Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct bonding of Orthodontic brackets
Description: Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect bonding of Orthodontic brackets
Description: Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect bonding of Orthodontic brackets
Description: Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
Study: NCT03457701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
Study: NCT01207583

Intervention type: OTHER
Intervention: Non-interventional observational study
Description: Non-interventional observational study
Study: NCT01301157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Description: Proper quantity twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Description: Proper quantity twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Proper quantity twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovonex
Description: Proper quantity twice a day
Study: NCT02790476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters
Description: The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone.
Study: NCT03193424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
Study: NCT02102633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib 500 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 150 mg orally
Study: NCT00768729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF or Azathioprine
Description: 600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
Study: NCT01303575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV, STI and Pregnancy Prevention Curriculum
Description: A complete internet-based, It's Your Game...Keep It Real Intervention Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Curricula
Description: A computer-based, science education program that does not contain elements of sexual health education
Study: NCT00885547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium wilfordii (TW)
Description: 90 mg/d for 6 months